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U n c e r t a i n t ye x i s t sa st ow h e t h e rs i m i l a ro rd i ﬀerent mechanisms contribute to the pathogenesis of diﬀerent subtypes of multiple
sclerosis (MS). Detailed analysis of naive T cell homeostasis shows that patients with relapsing-remitting MS (RRMS) and with
primary progressive MS (PPMS) have early-onset thymic involution that causes reduced thymic output. The reduced thymic
output leads to secondary peripheral homeostatic alterations in na¨ ıve CD4 T-cells, which closely mimic T-cell alterations observed
in an experimental animal model of diabetes mellitus. Homeostatic T-cell receptor (TCR) signalling and proliferation of na¨ ıve T
cells are induced by self-peptides. Consequently, the ﬁndings of increased TCR signalling of na¨ ıve CD4 T-cells, without increased
proliferation, in PPMS, and the increased homeostatic proliferation of na¨ ıve CD4 T-cells in RRMS favour the development of
autoimmunity. Thus, it seems highly likely that peripheral T-cell alterations secondary to a thymic abnormality contribute to the
pathogenesis of both MS subtypes.
1.Introduction
MS is a chronic inﬂammatory and neurodegenerative dis-
order of the central nervous system. An ongoing issue is
whether similar or diﬀerent mechanisms contribute to the
pathogenesis of diﬀerent MS subtypes. Current opinion
implicates peripheral T cells in an autoimmune response
directed against CNS antigens as the pathogenetic mech-
anism in RRMS, but not in PPMS or in SPMS [1, 2].
Instead, some claim that CNS injury in progressive MS is
due to neurodegeneration [3], or as suggested recently, to a
neuroinﬂammatory process conﬁned within the blood brain
barrier [4].
The basis of autoimmunity in MS is a subject of
considerable interest. Over the past twenty years, work in
my laboratory investigated the possibility that a thymic
abnormality contributes to the pathogenesis of MS. We
initiallyfocusedonRRMS.TheresultsofourstudiesoftheT-
cell receptor (TCR) repertoire (see below) led us to question
whether RRMS patients have altered T-cell homeostasis.
We also considered the possibility that PPMS patients
share T-cell homeostatic alterations with RRMS patients.
Several studies suggest that T-cell homeostatic alterations
contribute to autoimmunity. The thymus has been shown
to have an important role in the regulation of experimental
autoimmune encephalomyelitis (EAE) [5]. Peripheral home-
ostatic T-cell responses to lymphopenia have a central role
in the development of experimental autoimmune diabetes
[6] and in patients after islet cell transplants [7]. In
rheumatoid arthritis, one group of investigators reported
homeostatic peripheral T-cell alterations, possibly secondary
to reduced thymic output although direct evidence of a
thymic alteration was not obtained [8]. As summarized
below, we have direct evidence of reduced thymic output
not only in RRMS but also in PPMS. This reduced thymic
output leads to peripheral homeostatic responses and T-
cell activation in both MS subtypes. It is proposed here,
analogous to lymphopenia-induced autoimmunity [6], that
reduced thymic output results in a homeostatic response
that contributes to the pathogenesis of both RRMS and
PPMS. That is, both subtypes of MS are disorders of T-cell
homeostasis.
2. Studies of the TCR Repertoire in RRMS
In 1993, Utz et al. reported that antigen-stimulated T-
cells from RRMS patients have major shifts in their overall
TCR diversity, that is, TCR repertoires [9]. This report
led us to question whether TCR repertoire shifts occur
in unstimulated T-cells from RRMS patients and whether2 Multiple Sclerosis International
these shifts could contribute to the pathogenesis of RRMS.
In order to address this possibility, we analyzed freshly
isolated naive CD4 T-cells, which by deﬁnition have not
been antigen-stimulated. We reasoned that changes in these
T cells would be independent of the immune response
in RRMS and precede the onset of RRMS. We studied
identical twins discordant for RRMS. In comparisons with
healthy identical twin pairs, both the aﬀected twins and
their healthy cotwins had TCR repertoire shifts, speciﬁcally
in the complementarity-determining 3 (CDR3) regions of
several TCR V beta gene segments [10]. Since we analyzed
na¨ ıve T-cells, the ﬁndings suggested that these shifts precede
RRMS and likely predispose to the development of RRMS.
Importantly, it seemed unlikely that these shifts were suﬃ-
cient to initiate MS by themselves, as both the healthy and
the aﬀected members of the discordant twin pairs had TCR
repertoire shifts [10].
We considered several possible explanations for the
TCR repertoire shifts. Firstly, we excluded genetic diﬀer-
ences between twin pairs, including HLA diﬀerences, as
explanations for the TCR repertoire shifts (see [10]f o ra
detailed discussion). In this regard, a genetic inﬂuence on
CDR3 repertoires is highly unlikely; 90% of TCR diversity
is randomly generated by nucleotide additions within the
CDR3 region during thymopoiesis and these additions
are independent of genetic background [11]. Secondly, a
stochastic basis is improbable, since both members of the
discordant MS twin pairs shared the TCR repertoire shifts.
Thirdly, and a more likely explanation is that unknown
environmental factors aﬀected both members of each dis-
cordant twin pair so as to alter TCR repertoire formation
in the thymus; we have no direct evidence to support this
explanation. Since the thymus has a central role in na¨ ıve T-
cell generation and T-cell homeostasis (reviewed in [12]), we
hypothesized that MS is a disorder of T-cell homeostasis.
3. T-Cell Homeostasis: ABrief Summary
Homeostasis is the capacity of a biological system to main-
tainits equilibriumby physiologicalmechanisms in response
to change [13]. T-cell homeostasis is tightly regulated and
includes a balance between thymic output, which decreases
exponentially with increasing age, delivery of death and sur-
vival signals, na¨ ıve T-cell diﬀerentiation into memory cells,
and peripheral T-cell proliferation. This T-cell proliferation
is an important contributor to T-cell homeostasis in healthy
individuals, as it helps maintain T-cell numbers in the face of
thymic involution [14].
4. Reduced Thymic Output in
RRMS andinPPMS
Signal joint T-cell receptor excision circles (sjTRECs) are
often quantiﬁed as a measure of thymic output [14–26].
sjTRECs form as by-products of TCRα gene rearrangement
during late thymopoiesis. These sjTRECs are cytoplasmic
circular DNA fragments (episomes) and cannot replicate
during mitosis [14, 15]. Consequently, reduced sjTREC fre-
quencies, that is, reduced sjTRECs in constant cell numbers
(e.g., sjTRECs/106 cells), could be due either to reduced
thymic output or to increased peripheral T-cell proliferation
[14, 15]. In RRMS, various investigators report reduced
sjTREC frequencies in peripheral blood mononuclear cells
(PBMC) or in T subsets. As one might expect from the
diﬃculty in interpreting sjTREC frequencies, some claim
reduced thymic output whereas others raise the possibility
of increased peripheral T cell proliferation in RRMS [18–
22]. An important reason for the diﬀerent interpretations
is that none of these studies included a direct measure of
thymicoutput,whichexcludesthecontributionofperipheral
T cell proliferation. Na¨ ıve T cells contain the vast majority
of sjTRECs whereas memory T cells contain very few
sjTRECs [14]. Memory T cell numbers increase with age
[27] and might also vary with the magnitude of the chronic
immune response in MS. Consequently, any demonstration
of patient-control diﬀerences in the sjTREC content of
PBMC or total T cells could reﬂect, in part, diﬀerences in
memory T-cell numbers between patients and controls. In
order to avoid these diﬃculties in interpreting sjTRECs, we
isolated na¨ ıve T subsets and studied their sjTREC content. In
order to exclude possible treatment inﬂuences on sjTRECs,
we only studied RRMS patients in remission; none had been
treated with corticosteroids, immunomodulatory agents in
the year prior to the study, and none of the patients had ever
received cytotoxic agents. Since most RRMS patients receive
some form of treatment, we could not identify suﬃcient
patients to control for disease duration. No patient had overt
evidence of thymic disease such as myasthenia gravis. In one
study, we found that RRMS patients under, but not over, age
40 have signiﬁcantly reduced sjTREC frequencies compared
to age-matched controls [23]. In a second study of both
RRMS and PPMS patients, we observed that the sjTREC
frequencies of naive CD4 and na¨ ıve CD8 T cells decrease
exponentially with age in healthy controls [24], as shown
in Figures 1(a),a n d1(b). This ﬁnding is consistent with
several reports indicating that thymic output decreases with
increasing age [14, 15]. In contrast to controls, naive T-cell
sjTREC frequencies did not show a signiﬁcant decrease with
age in RRMS or in PPMS. Instead, the younger RRMS and
PPMS patients had lower sjTREC frequencies than controls
of a similar age, and these frequencies remained at low
levels with increasing age of the patients [24]. These ﬁndings
suggested that both RRMS and PPMS patients have reduced
thymic output.
Since sjTRECs are inﬂuenced not only by thymic output
but also by T cell division [14, 15], we sought direct evidence
of reduced thymic output in MS patients. Total sjTREC
numbers in the na¨ ıve T cell pool, for example, sjTRECs/mL
of peripheral blood, are unaﬀected by peripheral T-cell
proliferation and consequently provide a superior measure
of thymic output [25]. Total naive CD4 T-cell sjTRECs
were signiﬁcantly reduced in RRMS and PPMS patients
compared to controls (see Figure 1(c)), indicating reduced
thymic output in both MS subtypes [24]. To extend this
work, we exploited a mathematical model, which providesMultiple Sclerosis International 3
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Figure 1: sjTRECs in controls and patients. (a) Na¨ ıve CD4 sjTREC frequencies (sjTRECs/106 na¨ ıve CD4 T-cells) decreased signiﬁcantly with
age only in controls (P = 0.037). (b) Na¨ ıve CD8 sjTREC frequencies decreased with age only in controls (P = 0.037). (c) Total na¨ ıve CD4
sjTREC numbers decreased exponentially with age only in controls (P = 0.048). Median sjTRECs were higher in controls than in RRMS
(P = 0.03) or in PPMS (P = 0.007) with a trend towards higher sjTREC numbers in RRMS versus PPMS (P = 0.055). (d) Thymic export
(na¨ ıveCD4 T-cells/day) decreased withage only incontrols (r =− 0.564,P = 0.05).BothRRMS(P = 0.005) andPPMSpatients (P = 0.004)
had signiﬁcantly reduced median daily thymic export compared to controls.
the ﬁrst reported quantitative measure of thymic export (T-
cells/day). This model takes into account na¨ ıve CD4 T-cell
sjTREC content and the absolute number of na¨ ıve CD4 T-
cells and identiﬁes and excludes the contribution of T-cell
proliferation, measured by expression of the proliferation
marker Ki-67, to na¨ ıve CD4 T-cell sjTREC content [26].
ApplicationofthismodeldemonstratedthatbothRRMSand
PPMS patients have reduced thymic export of na¨ ıve CD4 T
cells/day compared to controls, and that thymic export is low
in young patients from both patient groups and remains low
with increasing age (see Figure 1(d)). Surprisingly, thymic
export of na¨ ıve CD4 T-cells/day was lower in PPMS than
RRMS [24]. Taken together, the quantitative data indicate
that both RRMS and PPMS patients have a major thymic
alteration with early-onset thymic involution and resulting
reduced thymic output [23, 24].
5.IncreasedNa¨ ıveCD4T-Cell
SurvivalSignalsinMS
The long-term maintenance of function and survival of
peripheral na¨ ıve Tcells depends upon TCR signalling via
self-peptide-MHC class II molecules and upon IL-7 recep-
tor (CD127) signalling via IL-7, which in turn induces
expression of the anti-apoptotic molecule Bcl-2 [12]. We4 Multiple Sclerosis International
questioned whether survival signals are increased in RRMS
and PPMS. In one study, we found apparently increased
expression of Bcl-2 by CD31-negative (CD31neg) cells from
RRMS patients versus controls [23]; CD31-positive na¨ ıve
CD4 T cells include CD4 recent thymic emigrants whereas
CD31neg cells are distant in origin from the thymus [16,
28]. We found increased expression of Bcl-2 by both na¨ ıve
CD4 and CD8 T cells from PPMS patients compared to
controls [24]. These ﬁndings suggest increased delivery of
survival signal in both patient groups, which may partly
compensate for the reduced thymic output in these patients,
that is, helps maintain the size of the peripheral naive T-cell
pools. Increased Bcl-2 expression may also have relevance for
MS susceptibility; overexpression of β- a r r e s t i n1 ,ap o s i t i v e
regulator of Bcl-2 expression, increases susceptibility to EAE,
and CD4 T cells in MS have increased expression of β-
arrestin 1 [29].
6. IncreasedNaiveT-Cell Proliferation and
TCRSignallinginMS
The magnitude of proliferation of early (CD3-CD4-CD8-)
thymocytes is the main determinant of thymic output. Pro-
liferation of early thymocytes decreases progressively with
age, which explains the progressive age-associated decreasing
thymic output that occurs in healthy individuals [30, 31]. We
used two strategies to assess peripheral homeostatic prolif-
eration; in all studies, we analyzed na¨ ıve T-cell expression
of the proliferation marker Ki-67, which is expressed in all
cells in the G1, S, G2, and M phases of the cell cycle [32]; in
one study, we quantiﬁed na¨ ıve CD4 T-cell βTRECs, which
are a byproduct of early thymocyte proliferation [30]. In
an early study, we reported increased Ki-67 proliferation
levels in na¨ ıve CD8 T cells from RRMS patients versus
controls [18]. In a later study, we reported progressive
age-associated reduction of na¨ ıve CD4 T-cell βTRECs in
RRMS patients versus controls. This ﬁnding suggested that
RRMS patients have increased na¨ ıve CD4 T-cell homeostatic
proliferation [23]; an increase in thymocyte proliferation
seems an unlikely explanation of the reduced βTRECs, as
such proliferation is inconsistent with thymic involutional
processes [30, 31]. We also attempted to use a more direct
measure of thymocyte proliferation, the sj/βTREC ratio;
to obtain this ratio some quantify either 6 or 10βTRECs,
extrapolate to 13βTRECs, and then calculate the sj/βTREC
ratio [31, 33]. After quantifying six βTRECs in cohorts of
RRMS patients and age-matched controls, we found that
the individual βTREC levels diﬀered signiﬁcantly from one
another. We concluded in our laboratory that calculations of
sj/βTREC ratios would not provide accurate, direct measures
of thymocyte proliferation [23]. Detailed comparisons of Ki-
67 expression levels in na¨ ıve CD4 T-subsets from RRMS
patients and controls did show, however, increased na¨ ıve
CD4 T-cell proliferation in RRMS, predominantly in the
CD31-positivecellshavingthehighestlevelsofCD31expres-
sion (CD31hi cells or CD4 recent thymic emigrants—for
details, see [23]) but also in CD31neg cells. Our proliferation
data suggest that increased peripheral T-cell proliferation
30
40
50
60
70
80
90
Controls
RRMS
PPMS
Linear (controls)
Linear (RRMS)
Linear (PPMS)
C
D
3
1
+
n
a
i
v
e
C
D
4
T
-
c
e
l
l
s
(
%
)
25 30 35 40 45 50 55 60 65
Age
Figure 2: Naive CD4 T-cell expression of CD31. The proportion of
na¨ ıve CD4 T-cells expressing CD31 showed a signiﬁcant decrease
with age only in PPMS (P = 0.031).
m a yp a r t l yc o n t r i b u t et or e d u c e ds j T R E C si nR R M S ,a s
suggestedinotherreports[18,22],but,asnotedinSection4,
reduced sjTRECs in RRMS are mainly due to reduced thymic
output.
Several reports emphasize that TCR signalling of CD31-
positive naive CD4 T cells induces loss of CD31 expres-
sion, which is accompanied by increased naive CD4 T-cell
proliferation [28, 34]. We analyzed the proportion of naive
CD4 T-cells expressing CD31 as a potential indicator of
increased proliferation in PPMS, in comparisons with RRMS
and controls. An age-associated decrease in this proportion
onlyinPPMS(seeFigure2)[24]initiallysuggestedincreased
naive CD4 T-cell proliferation in PPMS compared to the
other two groups. However, Ki-67 expression did not diﬀer
in PPMS from controls or RRMS patients [24]. Also, if
increased proliferation had occurred in PPMS, na¨ ıve CD4
T-cell sjTREC frequencies should also have decreased with
age, but that did not occur [24]. A recent study has showed
that TCR signalling does not induce total loss of CD31 from
the T-cell surface but rather cleavage and shedding of a
portion of CD31 containing the epitope recognized by the
commonly used anti-CD31 antibody [35]. Accordingly, our
data indicate increased TCR signalling of na¨ ıve CD4 T cells
in PPMS without increased proliferation.
7. Conclusions
The direct evidence for early-onset thymic involution and
reduced thymic output in RRMS, described above, is sup-
ported by the indirect evidence of reduced thymic output
from other laboratories [19–22]. To my knowledge, ours is
the only group to report reduced thymic output in PPMS.
One limitation to our studies is that we have no deﬁnite
evidence as to the basis of the reduced thymic output inMultiple Sclerosis International 5
MS although our TCR repertoire studies raise the possibility
that some unknown environmental factor/factors target(s)
the thymus in RRMS (see above). Direct analysis of thymic
export suggests that thymic alterations occur early in life
in RRMS and PPMS, either at the time of MS onset or
before and that the thymic “defect” persists throughout life,
as indicated by low but constant levels of thymic export
with increasing age. In other words, our ﬁndings suggest
an early onset of thymic involution in MS. One study of
immunoablation/autologous stem cell transplantation as a
treatmentofMSshowedthattheposttransplantMSpatients
“rebooted” their immune system such that the thymus
produced new T cells having a diverse TCR repertoire [36].
This ﬁnding is not inconsistent with our results; RRMS
patients over age 40 continue to generate recent thymic
emigrants, which contain the majority of na¨ ıve T cell TCR
diversity [37] although this generation is at signiﬁcantly
lower levels than age-matched controls [23].
A critical question is whether reduced thymic output
has relevance to the pathogenesis of MS. Both RRMS and
PPMS patients have increased naive CD4 T-cell expression
of Bcl-2 [23, 24]. Increased expression of this survival signal
may partly compensate for reduced thymic output in RRMS
and PPMS by helping to maintain the size of the na¨ ıve T-
cell pool. As noted in Section 5, increased expression of
this anti-apoptotic molecule may also increase susceptibility
to MS. Homeostatic proliferation induced by self-peptide
MHC constricts the TCR repertoire and inevitably expands
autoreactive T cells, particularly autoreactive CD31neg naive
CD4Tcells[28,34].Theincreasedhomeostaticproliferation
in RRMS is analogous to the homeostatic proliferation
that initiates autoimmune diabetes in a mouse model
[6], that is, it seems logical to implicate this process in
the pathogenesis of RRMS. TCR signalling causes partial
cleavage and shedding of CD31 from naive CD4 T cells
[35].ThissheddingabrogatestheactivityofCD31-associated
immunotyrosine-based inhibitory motifs (ITIMs) [35]. In
PPMS, increased TCR signalling of naive CD4 T cells,
presumablybyself-peptides,couldactivateself-reactivenaive
CD4 T cells and initiate autoimmune responses. Since
naive CD4 T cells have a central role in initiating immune
responses, including autoimmune responses in RRMS [38],
the peripheral TCR signalling/proliferative responses to
reduced thymic output likely initiate autoreactivity in PPMS
and RRMS. If this view is correct, it remains unresolved
as to why PPMS patients show minimal responses to anti-
inﬂammatory and immunosuppressive agents [39]a n dw h y
PPMS patients have a paucity of new MRI lesions [40].
Obviously, peripheral homeostatic naive T-cell responses to
early-onset thymic involution will persist throughout life
in PPMS and RRMS in order to maintain the naive T-
cell pool. Natural regulatory T cells (nTregs) are included
within the naive CD4 T subset [41] and show disturbed
development and function in SPMS [42]. One possibility
in PPMS is that early-onset thymic involution alters nTregs,
either quantitatively or qualitatively, so that CNS injury is
continuous without relapses, as suggested by one study of T-
cell regulation in PPMS [43]. Further analysis of regulatory
T-cell function in PPMS is essential to address this issue.
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